Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
In a new article series from the European Respiratory Review, researchers discuss what personalised medicine means for people with different lung diseases, beginning with asthma.
Personalised medicine recognises that the same disease can have different causes, symptoms and treatments for different individuals. It aims to achieve the best outcomes for each person by targeting treatment to each specific individual.
The articles authors discuss the value of this approach for understanding and treating asthma. They explain that the disease that we all call asthma is actually several different types of airway inflammation (swelling), each with different causes. This could lead to treatments targeted to each type.
Personalised medicine has already proved to benefit people with a type of asthma known as ‘severe eosionophilic asthma’. For other types, this approach is still relatively undeveloped.
One example the article authors discussed was the finding from the U-BIOPRED study that there was too much tumour necrosis factor (known as TNF – a substance in the body that causes swelling) produced in people with certain types of severe asthma. Targeting TNF has not been effective in previous studies that did not consider differences in asthma type. But future research that takes these differences into account might find anti-TNF helpful for people with certain types of severe asthma.
Overall the article explains that there is still a lot of work to do before personalised medicine is part of everyday treatment for people with asthma. However, the approach could help to reduce the number of treatments an individual might try before finding one that works.
These potential benefits rely on more good-quality research to improve the evidence behind the theories.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description